Neylan John F.'s Form 4 filing
Elicio Therapeutics, Inc. (ELTX) · filed Sep 21, 2021
- Accession no.
- 0001601485-21-000058
- Filed
- Sep 21, 2021
- Trade date
- Sep 20, 2021
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 1 non-derivative transaction. Open-market sales total $3.79K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Neylan John F.CIK 0001640447 | Officer (See Remarks) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 20, 2021 | Common Stock | SSaleDisposed | −376 | $10.07F2 | −$3,786.32 | 36,241 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.07 to $10.09 inclusive.
Referenced by the price of 1 transaction in Table I.
Remarks
Senior Vice President and Chief Medical Officer